BioLineRx’s BL-8040 gets FDA Orphan Medication Designation for stem cell mobilization treatment BioLineRx , a clinical-stage biopharmaceutical organization dedicated to identifying, developing and in-licensing promising therapeutic candidates, today that it all has received see from the U announced.S. Food & Medication Administration confirming an Orphan Medication Designation of BL-8040 as cure for stem cell mobilization, as well as the Orphan Medication Designation previously granted to BL-8040 as cure for Acute Myeloid Leukemia cialis online danmark .

Tolwani, University of Alabama; A. Vinnikova, Virginia Commonwealth University; H. Szerlip, Medical University of Gerogia; J. Ye, Western New England Transplant and Renal Associates; E. Paganini, Cleveland Clinic; L. Dworkin, Rhode Island Medical center; K. Finkel, University of Texas; and M. Kraus, Indiana University.. Bioartificial kidney speeds recovery, reduces mortality Another promising clinical trial for the bioartificial kidney offers researchers a lot more hope that next few years these devices will be obtainable to save lots of lives of individuals with acute renal failing.